Celltrion
Incheon, South Korea · Biopharma, Biotechnology, Manufacturing
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has a
Key facts
- Headquarters
- Incheon, South Korea
- Employees
- 3,200
- Industries
- Biopharma, Biotechnology, Manufacturing
- Website
- www.celltrion.com
- Company page
Recent activity at Celltrion
- : Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access.
- : Celltrion acquires Gifrer to boost EU presence
- : Celltrion Announces European Commission Approval of Three New Biosimilars to Enhance Patient Treatment Options.
- : Celltrion Receives Approval for New Pharmaceutical Plant in Songdo, Incheon
- : Celltrion Acquires iQone Healthcare Switzerland to Strengthen Its European Expansion
- : Celltrion acquires iQone Healthcare Switzerland to strengthen European expansion
- : Celltrion Launches Two-Year Analysis of Subcutaneous Infliximab (CT-P13 SC) for Managing Inflammatory Bowel Disease
Leadership
- Claudette Saucedo, Area Director, West Region | Biosimilars | Oncology
- Seyun Jung, Latam Regional Coordinator
- Tom Nusbickel, Chief Operating Officer
- Bonnie Zhang, Chief Financial Officer
- Jae Kim - Probst, Chief Executive Officer
- Ruth Catabran, Experienced Business Partner
- Tolga Bugdayci, Employee At Celltrion
- Naresh Kumar, Finance Manager
- Canan Kilic, Analysing and Reporting Sales Figures
- Joseph Lim, Finance Executive
- Jihye Kim, Lead of Procurement Planning Team
- Sai Kumar, Information Technology Support Specialist
Verified email and direct lines for Celltrion’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Celltrion files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Celltrion in the news
- Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013 - PR Newswire (Oct 22, 2026)
- 셀트리온 Celltrion - Celltrion (Sep 29, 2025)
- Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire (Jan 13, 2026)
- Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength - Business Wire (Aug 24, 2026)
- 셀트리온 Celltrion - Celltrion (Sep 29, 2025)
- Shaping a Better Future: Celltrion Releases 2024/25 Sustainability Report - Celltrion (Sep 29, 2025)
- Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger - Business Wire (Oct 23, 2023)
- Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) - PR Newswire (Jul 07, 2025)
Companies similar to Celltrion
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
- MacroGenics · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
- TerSera · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
- Bristol Myers Squibb · Biopharma, Biotechnology, Manufacturing, Pharmaceutical, Therapeutics
About Celltrion: questions and answers
What does Celltrion do?
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has a
Where is Celltrion headquartered?
Celltrion is headquartered in Incheon, South Korea.
How many employees does Celltrion have?
Celltrion has about 3,200 employees.
Who leads Celltrion?
Jae Kim - Probst is a Chief Executive Officer at Celltrion.
What is the latest news on Celltrion?
On Oct 26, 2026, Celltrion Secures Exclusive Supply Agreement for Omlyclo and Aptozma with U.S. Healthcare Company to Expand Market Access.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy